Monoclonal antibodies (mAbs) have transformed modern medicine [1]. However, their impact is limited as they are not accessible to all. In 2020 IAVI and Wellcome published a joint report “Expanding access
<p>Up to 10 million people could die annually by 2050 due to anti-microbial resistance (AMR), the UN Environment Programme (UNEP) said in this report, highlighting the need to curtail pollution created by the pharmaceuticals, agricultural and healthcare sectors.</p>
According to the World Health Organisation (WHO), Colistin is a “reserve” antibiotic, which means it is supposed to be considered a “last-resort” option in treatment and used only in the most severe circumstances,
<p>If no action is taken, drug-resistant diseases could cause 10 million deaths each year by 2050 and damage to the economy as catastrophic as during the 2008-2009 global financial crisis warns this report by the UN Ad hoc Interagency Coordinating Group on Antimicrobial Resistance. By 2030, antimicrobial resistance could force up to 24 million people into extreme poverty.</p>
